---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-006131"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:25:42.505211+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling

## Summary
- Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.
- Cash $12.5M; raised ~$8.0M net in Feb 2024 public offering.
- Phase 3 LEVEL study for PH-HFpEF enrolling; 24 sites initiated, 152 patients planned.
- Secured global development/commercial rights to levosimendan in PH-HFpEF; new patent issued (US 11,969,424).
- Topline data from LEVEL expected second half 2025.

## SEC filing metadata
- accession: 0001654954-24-006131
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/0001654954-24-006131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-006131
- JSON: https://secwatch.observer/filing/0001654954-24-006131.json
- Plain text: https://secwatch.observer/filing/0001654954-24-006131.txt

## Key facts
- Earnings Releases
  TENAX THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income $3.8 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $3.8 million
  - Result: reported results
  source text: Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/0001654954-24-006131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.